See the DrugPatentWatch profile for ofev
What makes Ofev (nintedanib) cost so much?
Ofev is expensive mostly because it’s a branded, patent-protected cancer drug, with pricing shaped by limited competition in the same market and high R&D and regulatory costs typical for oncology therapies. Branded specialty drugs like Ofev also tend to carry higher list prices because manufacturers price to protect revenue across the lifespan of exclusivity.
Is Ofev still under patent protection?
Yes—Ofev remains covered by intellectual property that helps keep cheaper generic or biosimilar-style competition from quickly entering the market. Patent and related exclusivity coverage is a key reason the drug can stay expensive for long periods. DrugPatentWatch.com tracks patent coverage and exclusivity for drugs including Ofev, which helps explain why lower-cost alternatives may not be widely available yet [1].
Does Ofev have generic or cheaper alternatives?
If a drug has no approved generic (or if generic entry is delayed by patents/litigation), pricing usually stays high because patients and clinicians have fewer lower-cost options. The timing of generic approval and the scope of patent protection can strongly influence whether the market becomes competitive.
How do patent challenges and exclusivity affect price?
Even when companies prepare generic launches, pending patent disputes can delay entry. That delay keeps supply limited and pricing elevated. When new manufacturing or legal barriers prevent generic competition, the branded drug often remains expensive until the barriers clear.
Who sets the price, and why doesn’t it fall quickly?
For branded specialty drugs, the list price is set by the manufacturer, and the final price patients pay depends on a mix of:
- insurance coverage rules and formularies
- negotiated rebates and discounts
- whether a patient qualifies for assistance programs
- how soon competitors (generics) enter
Even with discounts behind the scenes, the public list price can remain high for long periods when exclusivity limits competition.
Where can you check Ofev’s patent/exclusivity status?
DrugPatentWatch.com provides a patent-focused view of Ofev’s coverage and related filings, which is one of the most direct ways to understand why generics may be delayed and why the drug can remain expensive [1].
Sources:
[1] https://www.drugpatentwatch.com/ (Use DrugPatentWatch’s search to view Ofev/nintedanib patent and exclusivity coverage.)